莫西沙星联合无创通气呼吸机对慢阻肺合并呼吸衰竭患者骨骼肌泛素-蛋白酶体及心功能的影响

Effects of Moxifloxacin Combined with Noninvasive Ventilation Ventilator on Skeletal Muscle Ubiquitin-proteasome and Cardiac Function in Patients with Chronic Obstructive Pulmonary Diseases Combined with Respiratory Failure

目的 研究莫西沙星联合无创通气呼吸机对慢阻肺合并呼吸衰竭患者骨骼肌泛素-蛋白酶体及心功能的影响。方法 选取2018年10月—2020年5月吉林省人民医院收治的97例慢阻肺合并呼吸衰竭患者,随机分为观察组和对照组,对照组48例患者采用常规抗感染治疗,观察组49例患者在对照组的基础上采用莫西沙星联合无创通气呼吸机治疗,观察对比两组治疗前后的临床疗效、血清炎症因子水平、骨骼肌内基因表达水平及心律、呼吸、PaO_(2)。结果 治疗后,观察组HR(84.40±9.97)次/min、RR(18.54±1.28)次/min、PaO_(2)(85.85±11.06)mmHg均优于对照组的(95.03±10.39)次/min、(23.57±1.89)次/min、(79.83±10.97)mmHg,差异有统计学意义(t=5.142、15.375、2.691,P<0.05);治疗后,观察组各炎性因子水平均优于对照组,差异有统计学意义(P<0.05);观察组泛素(8.25±3.05)KDa、E2(4.40±2.21)pmol/L、E3(8.64±3.21)mg/24 h均低于对照组的(10.21±5.51)KDa、(9.03±4.39)pmol/L、(14.52±6.27)mg/24 h,差异有统计学意义(P<0.05)。结论 莫西沙星联合无创通气呼吸机对慢阻肺合并呼吸衰竭患者的疗效更好,能有效改善患者的心功能,减少骨骼肌蛋白丢失,值得进一步的临床研究。

Objective To study the effects of moxifloxacin combined with noninvasive ventilation ventilator on skeletal muscle ubiquitinproteasome and cardiac function in patients with chronic obstructive pulmonary diseases combined with respiratory failure.Methods 97 patients with chronic obstructive pulmonary diseases combined with respiratory failure admitted to Jilin Provincial People's Hospital from October 2018 to May 2020 were selected and randomly divided into observation group and control group.48 patients in the control group were treated with conventional anti-infection therapy,and 49 patients in the observation group were treated with moxifloxacin combined with noninvasive ventilation ventilator on the basis of the control group.The clinical efficacy,serum inflammatory factor level,gene expression level in skeletal muscle and heart rate,breathe and PaO_(2) of the two groups before and after treatment were observed and compared.Results After treatment,the HR(84.40±9.97)times/min,RR(18.54±1.28)times/min,PaO_(2)(85.85±11.06)mmHg in the observation group were better than those in the control group(95.03±10.39)times/min,(23.57±1.89)times/min,(79.83±10.97)mmHg,the difference was statistically significant(t=5.142,15.375,2.691,P<0.05).After treatment,the levels of various inflammatory factors in the observation group were better than those in the control group,with a statistically significant difference(P<0.05).The observation group showed lower levels of ubiquitin(8.25±3.05)KDa,E2(4.40±2.21)pmol/L,and E3(8.64±3.21)mg/24 hours compared to the control group(10.21±5.51)KDa,(9.03±4.39)pmol/L,and(14.52±6.27)mg/24 hours,the difference was statistically significant(P<0.05).Conclusion Moxifloxacin combined with noninvasive ventilation ventilator is more effective in patients with chronic obstructive pulmonary disease combined with respiratory failure,and it can effectively improve patients'cardiac function and reduce skeletal muscle protein loss,which is worthy of further clinical study.